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ABSTRACT (196 words): 
 
Pancreas transplantation is a successful treatment for a selected group of people with type 1 
diabetes. Continued insulin production can decrease over time and identifying predictors of 
long-term graft function is key to improving survival. The aim of this study was to screen 
subjects for variation in the Caveolin-1 gene (Cav1), previously shown to correlate with long-
term kidney transplant function. We genotyped 435 pancreas transplant donors and 431 
recipients who had undergone pancreas transplantation at the Oxford Transplant Centre, UK, 
for all common variants in Cav1. Death-censored cumulative events were analysed using 
Kaplan-Meier and Cox regression. Unlike kidney transplantation, the rs4730751 variant in our 
pancreas donors or transplant recipients did not correlate with long-term graft function 
(P=0.331-0.905). Presence of rs3801995 TT genotype (P=0.009) and rs9920 CC/CT genotype 
(P=0.010) in our donors did however correlate with reduced long-term graft survival. 
Multivariate Cox regression (adjusted for donor and recipient transplant factors) confirmed the 
association of rs3801995 (P=0.009, HR=1.83;[95% CI=1.16-2.89]) and rs9920 (P=0.037, 
HR=1.63;[95% CI=1.03-2.73]) with long-term graft function. This is the first study to provide 
evidence that donor Cav1 genotype correlates with long-term pancreas graft function. 
Screening Cav1 in other datasets is required to confirm these pilot results. 
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BRIEF COMMUNICATION (3000 words maximum- 3000 words) 
 
INTRODUCTION 
 
Whole organ pancreas transplantation has the potential to provide life-long independence from 
exogenous insulin injections for people with type 1 diabetes (T1D) with poor glycaemic control 
and/or severe secondary complications (1, 2). Whilst early complications are common after 
transplantation, patient survival is >95%-98% at one year (3). Patients with a functioning 
pancreas transplant achieve insulin independence, improved hypoglycaemic awareness and 
there is increasing evidence of stabilisation or improvement in secondary diabetic 
complications (2). Although graft survival can exceed 20 years, graft function decreases over 
time (4). Although one year post transplant 85% of patients have a functioning pancreas graft 
(defined as insulin production), this falls to around 68% five years post-transplant (5). Loss of 
pancreas graft function, and subsequent return to exogenous insulin, is strongly associated with 
transplant patient mortality (6). Hyperglycaemia is a late feature of graft loss, by which time 
graft failure is usually irreversible. Currently it is not possible to predict when a graft is likely 
to fail.  
 
Whilst recent progress has been made in identifying clinical features associated with long-term 
pancreas transplant function, including development of de novo HLA alloantibodies (Hazard 
Ratio (HR)=4.66) (7) and an abnormal glucose tolerance test within two weeks after 
transplantation (HR=1.66) (8), only limited work has been undertaken looking at potential 
genetic associations with long-term pancreas transplant function. Work in the related, but more 
established, field of renal transplantation, has identified several potential genetic factors that 
correlate with long-term graft function (9-12) including, most convincingly, variation in the 
Caveolin-1 gene (Cav1), which encodes invaginations within the plasma membrane involved 
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in signal transduction and tissue fibrosis (13).  Presence of the Cav1 rs4730751 single 
nucleotide polymorphism (SNP) AA genotype in kidney donors was associated with increased 
risk of allograft failure, HR=1.56-1.97, in two independent UK cohorts (13).  Importantly, the 
effect size of this variant is comparable with that of female donor gender and donor 
hypertension, both recognised as relevant clinical indicators of transplant success. Whilst some 
small datasets have looked at potential genetic predictors of long-term pancreas graft function, 
including MICA/MICB, HLA-DRA and vitamin D (14-16), currently no genetic factors have 
been identified that correlate with long-term pancreas function. Identifying genetic factors 
associated with long-term pancreas function might provide an opportunity to intervene early to 
preserve beta cell function and prolong the benefits of a functioning graft.   
 
The aim of this study, therefore, was to screen all common variation within Cav1 in 435 
pancreas transplant donors and 431 recipients who underwent transplantation at the Oxford 
Transplant Centre, UK, to determine if Cav1 variation is associated with long-term pancreas 
graft function. 
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MATERIALS AND METHODS 
 
Patients 
This was a single centre, retrospective study. Anonymized DNA and matched clinical data, 
including both donor and recipient transplant related variables (Table 1), were obtained 
retrospectively from pancreas transplant donors and recipients at the Oxford Transplant Centre, 
UK, between 2002 and 2012. This was limited to those in which surplus DNA was available 
within our tissue typing laboratory (originally obtained from whole blood to undertake tissue 
matching and stored for further testing as clinically indicated).  The patient cohort consisted of 
DNA from 435 transplants; 315 (72.4%) simultaneous pancreas kidney (SPK), 120 isolated 
pancreas (IP) transplants, including 68 (15.6%) pancreas after kidney transplant (PAK), 38 
(8.7%) pancreas transplants alone (PTA) and 14 second transplants (3.2%) (Table 1).  The 
study was approved by the United Kingdom National Research Ethics Committee (REC 
reference 12/SC/0655; Protocol dated 22/10/12 Version 1.0). 
 
As previously described (7), all transplants were performed with systemic venous drainage.  
Enteric ductal drainage was used in all except three recipients, who received IP transplants with 
bladder drainage due to a change in center protocol. All recipients received alemtuzumab 
induction immunosuppression (Campath 30 mg, days 1 and 2, Genzyme Corporation, Boston, 
MA), with maintenance immunosuppression therapy consisting of tacrolimus, initially at 0.5 
mg/kg twice a day (bd), titrated to maintain trough levels between 8 ng/mL and 10 ng/mL 
throughout the follow-up, and mycophenolate mofetil, at 750 mg bd, with dose adjustments as 
clinically indicated (7). Trough serum tacrolimus levels and absolute neutrophil counts were 
monitored regularly on an outpatient basis. Mycophenolate levels were not monitored. No 
steroids were used in maintenance immunotherapy. 
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Tag SNP Selection and Genotyping 
Genotyping data for the 36.39kb Cav1 region (Phase 2, NCBI Build 36, Caucasian (CEU) 
population) was downloaded from the International Haplotype Mapping Project website 
(http://www.hapmap.org).  Our analysis of Hapmap genotyping data identified 53 SNPs with 
minor allele frequencies (MAF) of >5% in the CEU population within this region.  Tagger 
pairwise function within Hapmap was used to assign tag SNPs.  Twelve tag SNPs: rs4730751, 
rs959173, rs3801995, rs12672038, rs9886215, rs11773845, rs926198, rs3779512, rs9920, 
rs1049337, rs3807986 and rs4730748, were chosen to capture the majority of the common 
variation within this gene and the surrounding area with a minimum r2 of 0.80 (for information 
on SNPs captured see Supplementary Table 1). All tag SNP genotypes represent the nucleotide 
variants present at that SNP associated with a given trait (see Supplementary Table 1 for further 
details on location and nucleotides present at each SNP). We had >0.80 power to detect an 
OR>1.51 for MAF=0.10.  Fluorescence-based genotyping assays for all SNPs were purchased 
from Life Technologies, Paisley, UK and genotyped on an ABI7900HT using Taqman® 
genotyping technologies (Life Technologies, Paisley, UK). All variants were subject to Hardy 
Weinberg Equilibrium (HWE) analysis to ensure accurate genotyping (P<0.05 was considered 
significant deviation from HWE). 
 
Outcome Measures and Statistical Analysis 
Anonymized demographic data and donor and recipient transplant related variables were 
extracted for all samples (Table 1). Quantitative parametric data were compared between 
groups using Student’s t-test or the Mann–Whitney U test in the case of nonparametric 
distribution. Cross-tabulated data were analysed by the chi-squared test.  Our primary outcome 
measure was defined as graft failure.  Return to exogenous insulin was used as a surrogate 
marker of graft failure (pancreas graft biopsies were not performed as part of the clinical 
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protocol).  A secondary outcome measure in our SPK patients was kidney graft failure, defined 
as return to kidney dialysis. Death censored cumulative events were analysed using Kaplan-
Meier methods, with the log-rank test used for intergroup comparison. Time-to-event 
analyses were performed using a Cox proportional hazards model. Gene variation and other 
relevant clinical/demographic characteristics were initially examined by a series of univariate 
analyses, followed by multiple regression analysis incorporating any variables showing 
evidence of univariate association (P<0.20). Statistical packages IBM SPSS Statistics 20 
(IBM United Kingdom Limited, Portsmouth, UK) and MINITAB 16 (MINITAB LTD, 
Coventry, United Kingdom) was used for all data analysis. 
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RESULTS 
 
Demographics 
Four hundred and thirty five pancreas transplants were included in this study (Table 1).  Three 
hundred and fifteen (72.4%) received an SPK transplant, and 120 (27.6%) received an Isolated 
Pancreas (IP) transplant. The PTA, PAK and second pancreas transplant groups had equivalent 
graft outcomes. The SPK group had comparatively superior graft outcomes (as previously 
reported (8)). Two hundred and ninety one (92.7%) SPK recipients received pancreases from 
donors after brainstem death (DBD) compared to 80 (66.7%) of IP recipients. This difference 
was statistically significant (P=6.00x10-12) and was principally due to UK organ allocation 
procedures (previously described (7)). A difference in donor BMI between SPK (Mean 
BMI=24.25) and IP (Mean BMI=23.28) groups was also detected, which could be due to 
differences in allocation scoring for SPK vs IP. The groups were otherwise comparable for 
donor and recipient characteristics, and cold ischemia time (P=0.807-0.090) (Table 1).  
 
Cav1 Genotyping in Donors 
In the pancreas transplant donors all 12 tag SNPs screened were in HWE (P=0.96-0.06) 
(Supplementary Table 2).  Within our transplant recipient cohort there were 84 events and 351 
censored events, with median follow up of 42 months. Kaplan-Meier analysis of death-
censored pancreas allograft function, revealed presence of the Cav1 rs4730751 AA genotype 
variant, previously shown to correlate with decreased allograft function in kidney transplants 
(13), was not associated with decreased long-term pancreas graft survival (P=0.331) (Figure 
1).  Presence of the Cav1 rs3801995 TT genotype however did correlate with reduced median 
graft survival (78 months) compared to donors with CT (98 months) or CC (111 months) 
genotypes (P=0.009) (Figure 1).  Presence of the Cav1 rs9920 CC and CT genotype (genotypes 
9 
 
were grouped together as only one donor had the CC genotype) also correlated with reduced 
median graft survival (93 months) compared to the TT genotype (112 months) (P=0.010). None 
of the other nine Cav1 tag SNPs screened in the donors showed any association with long-term 
graft function (P=0.792-0.100). 
 
Cav1 Genotyping in Recipients 
In the pancreas transplant recipients, rs9920 (P=0.02) and rs3807986 (P=0.03) were out of 
HWE, suggesting the results should be viewed with caution.  All other Cav1 tag SNPs screened 
in the recipients were in HWE (0.96-0.10) (Supplementary Table 2).  None of the twelve Cav1 
tag SNPs screened in the recipient was shown to influence long-term pancreas function 
(P=0.986-0.066) (see Figure 1 for rs4730751, rs3801995 and rs9920 Kaplan-Meier plots). 
 
Multivariate Analysis of Donor Cav1 r3801995 and rs9920 SNPs 
Gene variation and other clinical/demographic features of the cohort were analysed by Cox 
regression. Initial univariate analysis confirmed association of donor rs3801995 TT genotype 
(P=0.004, HR=2.74 [95% confidence intervals (CI)=1.38-5.44]) and rs9920 CC/CT genotype 
(P=0.037, HR=1.83 [95% CI=1.14-2.93]) with reduced long-term graft function.  Additionally, 
univariate analysis identified operation type (Second operation P=1.04x10-4, PAK P=0.037 and 
PTA P=0.009 compared against SPK), donor type (0.097), donor age (P=0.149) and recipient 
gender (0.177) as showing some univariate association (Table 2). Multivariate analysis of the 
rs3801995 SNP and clinical features, further supported a role for rs3801995 TT genotype in 
reduced long-term graft function (P=0.009, HR=1.83 [95% CI=1.16-2.89]), along with second 
operation (P=2.71x10-5, HR=5.05 [95% CI=2.37-10.76]) and PTA operation (P=0.032, 
HR=1.80 [95% CI=1.06-3.42] compared to SPK.  Multivariate analysis of the rs9920 SNP 
10 
 
supported association of the CC/CT genotype (P=0.037, HR=1.63 [95% CI=1.03-2.73]), along 
with second operation (P=0.005, HR=2.25 [1.28-3.97]), with reduced long-term graft function. 
 
As multivariate analysis identified second transplant as being associated with reduced long-
term pancreas function compared to SPK, we wanted to ensure presence of a second transplant 
was not driving rs3801995 TT or rs9920 CC/CT genotype associations.  We repeated our 
Kaplan-Meier analysis removing all 14 second transplants and both rs3801995 TT genotype 
(Log Rank P=0.004) and rs9920 CC/CT genotype (Log Rank P=0.010) remained associated 
with reduced long-term pancreas function, with rs4730751 still showing no association with 
long-term pancreas transplant function (P=0.493) (Supplementary Figure 1).  Multivariate 
analysis further confirmed a role for rs3801995 TT genotype (P=0.011, HR=2.52 [95% 
CI=1.23-5.17] and rs9920 CC/CT genotype (P=0.043, HR=1.67 [95% CI=1.02-2.80] in 
reduced long-term pancreas function (Supplementary Table 3), suggesting that over-
representation of second transplants within these genotypes was not driving this effect.  
Interestingly, rs11773845 AA genotype in our single transplant only donor cohort showed a 
borderline association with reduced long-term graft function (P=0.053), however this effect 
was not present after multivariate analysis (P=0.153) (data not shown). No other Cav1 tag SNP 
in the single transplant only donors showed any association with long-term graft function 
(P=0.866-0.086). None of the 12 Cav1 tag SNPs screened in the recipients undergoing a single 
transplant were associated with graft survival (P=0.997-0.057, data not shown). 
 
Role of Cav1 on long-term kidney function in our SPK transplants 
As a result of the link between Cav1 variation and long-term kidney transplant function (13), 
we also investigated Cav1 in our SPKs for a role in long-term kidney function.  When looking 
at kidney outcomes, there were 25 events and 269 censored events, with a median follow up of 
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45 months.  When investigating Cav1 SNP variation on kidney transplant outcome none of the 
12 tag SNPs screened showed any association with long-term kidney transplant outcome 
(P=0.123-0.938), including rs4730751 previously associated with long-term kidney function 
(13). In the SPK recipients, none of the 12 tag SNPs showed any association with kidney 
outcome (P=0.996-0.128). The rs959173 SNP showed weak association with long-term kidney 
transplant survival (P=0.049), being driven by three recipients with CC genotypes.  When 
combining rs959173 CC and CT genotypes compared against TT genotypes no association 
with long-term transplant function was detected (P=0.819) suggesting the original association 
was probably due to small numbers of CC genotypes. No other Cav1 tag SNP in the recipients 
showed any association with long-term kidney function (P=0.987-0.436). 
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DISCUSSION 
 
Screening all common variation within Cav1 in our Oxford pancreas transplant donors revealed 
presence of rs3801995 TT genotype and rs9920 CC/CT genotypes correlated with reduced 
long-term graft function. This is the first time a potential role for Cav1 variation in long-term 
pancreas transplant outcome has been reported. Interestingly however, we did not detect a role 
for rs4730751 genotype, previously reported to be associated with long-term kidney transplant 
function (13), in reduced long-term pancreas transplant or long-term kidney transplant function 
in our SPK patients.  
 
Further support for Cav1 in long-term transplant outcomes comes from 503 lung transplant 
recipients where Cav1 rs3807989 GG genotype (tagged by rs11773845 in our cohort) was 
associated with greater mortality (P=0.04) (17). In an independent lung transplant cohort, 
screening four Cav1 variants (rs3807989, rs3807994 (tagged by rs3801995 in our cohort), 
rs10256914 (tagged by rs4730751 in our cohort) and rs12154695) in 20 patients with 
bronchiolitis obliterans syndrome (BOS), a characteristic of chronic allograft rejection after 
lung transplant, compared to 80 lung transplant recipients without BOS, revealed that 35% of 
BOS positive recipients had the rs3807989 TT genotype compared to 8% of BOS negative 
recipients (OR=6.13 [95% CI=1.85-20.41]) (18). Genotyping of 11 of our 12 Cav1 tag SNPs 
(rs4730748 was not screened) in large T1D collections (>7500 cases and >9045 controls) 
showed no association with T1D (19, 20), further suggesting that Cav1 variation plays a direct 
role in transplant survival. 
 
Caveolin-1 is an essential component of caveolae, small invaginations within the plasma 
membrane which act as specialized lipid rafts involved in cell signal transduction and protein 
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interaction (21-24). Caveolin-1 plays a key role in numerous tissue remodelling and fibrotic 
pathways, including regulating TGF-β1 signalling/expression, controlling cell matrix 
remodelling, fibroblast adhesion/migration and in cell stretching, proliferation and apoptosis 
(22, 25).  Decreased Cav1 expression has also been reported in affected tissues from several 
human fibrotic diseases including idiopathic pulmonary fibrosis, scleroderma and systemic 
sclerosis, with re-introduction of Cav1 function shown to rescue these phenotypes (25). Upon 
histological assessment of kidney graft failure, recipients who received donor organs with the 
rs4730751 AA genotype, had a predominant increase in interstitial fibrosis compared to donors 
with non-AA genotypes (13). Only Cav1 variation in the donors, and not the recipients, was 
shown to play a role in long-term pancreas graft function, further suggesting that this effect is 
intrinsic to the donor organ rather than the recipient.  Whilst our clinical protocol does not 
allow for routine biopsy and histological grading of pancreas graft failure, making it difficult 
to assess the degree of fibrosis, increased fibrosis due to Cav1 variation could be affecting 
long-term pancreas function.  
 
Interestingly, Cav1 knockout mice not only show impaired fibrosis but also exhibit lipid and 
metabolic disorders including insulin resistance (21, 26).  Caveolin-1 is an essential scaffolding 
protein required for correct folding of the insulin receptor (IR), and without Cav1 the IR is not 
correctly formed, leading to insulin resistance (21, 24). Humans with severe insulin resistance 
have been found to have mutations within the IR caveolin binding motif (27-30), suggesting 
Cav1 could be contributing to reduced long-term graft function through other mechanisms in 
addition to fibrosis. 
 
It is interesting that we did not detect evidence for association of rs4730751, previously 
associated with kidney transplant outcomes, with either pancreas or kidney outcome in our 
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cohort. There are several potential reasons for this, i) differences in patient selection or time 
for follow up for renal transplant compared to those selected for SPK or IP transplant, ii) a 
functioning pancreas graft is known to extend kidney transplant function and may negate 
effects of rs4730751 in our cohort, iii) the rs4730751 SNP could have a smaller effect on long-
term pancreas transplant function which we are not currently powered to detect or iv) whilst 
Cav1 SNP frequencies in our Oxford Pancreas and Birmingham Kidney transplant cohorts 
were similar (13) (data not shown), subtle geographical differences in Cav1 SNP allele 
frequency between these populations could be affecting their role in transplant outcome.   
 
There are limitations to this study that should be considered when interpreting the results.  First, 
whilst the majority of our pancreas donors and recipients were Caucasian (>95%), we do not 
routinely store donor or recipient ethnicity within our centre as part of our clinical protocol. 
Reassuringly, all Cav1 tag SNPs in our donors were in HWE, which would be unlikely if ethnic 
differences were contributing to the variation seen in Cav1 tag SNP genotype frequencies.  As 
Cav1 SNP frequencies vary between different ethnic groups, and it is worth noting that effects 
found in our mainly white Caucasian dataset need to be replicated in other ethnic groups before 
inferences can be made on the role of Cav1 in non-Caucasian populations. Second, we have 
only been able to study a single data set, and as such data should be viewed as preliminary and 
awaiting replication. Before the clinical utility of this variant can be established further 
screening of Cav1 and fine-mapping the surrounding region in a second, and ideally larger 
independent pancreas transplant cohorts, will be required to confirm the association and that 
the primary effect, if present, is the result of polymorphism within Cav1 itself.  Once 
independent replication of these associations has been achieved, functional studies will enable 
us to determine how Cav1 variation in the donor is affecting gene expression and function 
leading to reduced long-term graft function, whilst being mindful of how features such as donor 
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age and donor type (DBD vs DCD) could be impacting upon Cav1 expression.  This new found 
knowledge can then be translated clinically into the identification of novel drugs, or 
repurposing of currently available drugs, to extend long-term graft function in patients carrying 
risk Cav1 genotypes. 
 
In summary, this study is the first to screen Cav1 in pancreas transplant donors and recipients 
and provide preliminary evidence for a role of Cav1 variation in donors in long-term pancreas 
transplant function. Replication of these Cav1 data in additional pancreas transplant cohorts is 
now required to confirm these potentially important findings.   
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FIGURE LEGENDS 
 
Figure 1: Kaplan-Meier Plots for role Cav1 rs4730751, rs3801995 and rs9920 SNP 
Variation in Oxford Transplant Centre Donors and Recipients on Long-term Pancreas 
Graft function A: Kaplan-Meier plot for variation of Cav1 rs4730751 in Pancreas 
Transplant Donors, B: Kaplan-Meier plot for variation of Cav1 rs4730751 in Pancreas 
Transplant Recipients, C: Kaplan-Meier plot for variation of Cav1 rs3801995 in Pancreas 
Transplant Donors, D: Kaplan-Meier plot for variation of Cav1 rs3801995 in Pancreas 
Transplant Recipients, E: Kaplan-Meier plot for variation of Cav1 rs9902 in Pancreas 
Transplant Donors & F: Kaplan-Meier plot for variation of Cav1 rs9902 in Pancreas 
Transplant Recipients 
 
Table 1: Characteristics of 435 Pancreas Transplant Donors and Recipients from the 
Oxford Transplant Centre 
Data are expressed as numbers (%) unless otherwise stated. For age and BMI the mean is 
given with the standard deviation in brackets. Cold Ischemia Time (CIT), Body Mass Index 
(BMI) 
Table 2: Univariate and Multivariate Analysis of Cav1 rs3801995 and rs9920 Donor 
Genotype on Long-term Pancreas Transplant Function  
Bold represents any association seen after univariate analysis (P<0.20) or multivariate analysis 
(P<0.05). Simultaneous Pancreas Kidney (SPK, Pancreas After kidney (PAK), Pancreas 
Transplant Alone (PTA), Second Pancreas Transplant (2ND), Hazard Ratio (HR), Human 
Leukocyte Antigen (HLA), Body Mass Index (BMI), Donor After Brainstem Death (DBD) & 
Donor After Circulatory Death (DCD) 
 
DESCRIPTION OF SUPPORTING MATERIAL 
 
Supplementary Figure S1: Kaplan-Meier Plots for role of Cav1 rs4730751, rs3801995 and 
rs9920 SNP variation in Oxford Transplant Centre Donors and Recipients on Long-term 
Pancreas Graft function without those who received a second transplant A: Kaplan-Meier 
plot for variation of Cav1 rs4730751 in Pancreas Transplant Donors, B: Kaplan-Meier 
plot for variation of Cav1 rs3801995 in Pancreas Transplant Donors, C: Kaplan-Meier 
plot for variation of Cav1 rs9920 in Pancreas Transplant Donors 
 
Supplementary Table S1: Cav1 tag SNPs screened in our Oxford Transplant Cohort 
and other common SNPs that they capture 
Supplementary Table S2: Cav1 Tag SNP genotype frequencies and Hardy Weinberg 
Equilibrium in our Oxford Pancreas Transplant donors and recipients 
Hardy Weinberg Equilibrium (HWE), Single Nucleotide Polymorphism (SNP) 
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Supplementary Table S3: Univariate and Multivariate Analysis of Cav1 rs3801995 and 
rs9920 Donor Genotype on Long-term Pancreas Transplant Function with all those with 
a Second Transplant Removed 
Bold represents any association seen after univariate analysis (P<0.20) or multivariate analysis 
(P<0.05). Simultaneous Pancreas Kidney (SPK, Pancreas After kidney (PAK), Pancreas 
Transplant Alone (PTA), Hazard Ratio (HR), Human Leukocyte Antigen (HLA), Body Mass 
Index (BMI), Donor After Brainstem Death (DBD) & Donor After Circulatory Death (DCD) 
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Figure 1: Kaplan-Meier Plots for role of Cav1 rs4730751, rs3801995 and rs9920 SNP
Variation in Oxford Transplant Centre Donors and Recipients on Long-Term
Pancreas Graft function A: Kaplan-Meier plot for variation of Cav1 rs4730751 in
Pancreas Transplant Donors, B: Kaplan-Meier plot for variation of Cav1 rs4730751
in Pancreas Transplant Recipients, C: Kaplan-Meier plot for variation of Cav1
rs3801995 in Pancreas Transplant Donors, D: Kaplan-Meier plot for variation of
Cav1 rs3801995 in Pancreas Transplant Recipients, E: Kaplan-Meier plot for
variation of Cav1 rs9902 in Pancreas Transplant Donors & F: Kaplan-Meier plot for
variation of Cav1 rs9902 in Pancreas Transplant Recipients
Table 1: Characteristics of 435 Pancreas Transplant Donors and Recipients from the Oxford Transplant Centre 
Data are expressed as numbers (%) unless otherwise stated. For age and BMI the mean is given with the standard deviation in brackets. Cold 
Ischemia Time (CIT), Body Mass Index (BMI), Standard Deviation (SD) 
Cohort Characteristics of Pancreas Transplant 
Donors and Recipients 
Total Cohort SPK IP P 
         
Type of 
Operation 
Simultaneous Pancreas Kidney (SPK) 315 (72.4) 315 (72.4)    
 Isolated Pancreas (IP) 120    120   
         
 Pancreas After Kidney (PAK) 68 (15.6)   68 (15.6)  
 Pancreas Transplant Alone (PTA) 38 (8.7)   38 (8.7)  
 Second Pancreas Transplant  14 (3.2)   14 (3.2)  
         
Donor  Donor after brainstem death (DBD) 371 (85.5) 291 (92.7) 80 (66.7) 6.00x10-12 
Type Donor after circulatory death (DCD) 63 (14.5) 23 (7.3) 40 (33.3)  
 CIT (SD) 688.31 (172.8) 683.1 (178.0) 702.1 (158.3) 0.158 
         
HLA  0-4 mismatches 297 (70.4) 215 (70.7) 82 (69.5) 0.804 
mismatches 5-6 mismatches 125 (29.6) 89 (29.3) 36 (30.5)  
         
Donor  Age, Mean (SD), year 36.80 (13.49) 37.48 (13.84) 35.03 (12.34) 0.090 
Donor BMI, Mean (SD) 23.98 (4.20) 24.25 (4.53) 23.28 (3.06) 0.031 
Donor 
Gender 
Female 213 (49.1) 160 (51.0) 53 (44.2) 0.206 
Male 221 (51.0) 154 (49.0) 67 (55.8)  
         
Recipient Age, Mean (SD), year 43.3 (8.05) 43.6 (8.01) 42.70 (8.14) 0.298 
Recipient BMI, Mean (SD) 25.32 (3.83) 25.39 (3.90) 25.15 (3.68) 0.807 
Recipient 
Gender 
Female 179 (41.2) 121 (38.5) 58 48.3 0.064 
Male 255 (58.8) 193 (61.5) 62 51.7  
         
Table 2: Univariate and Multivariate Analysis of Cav1 rs3801995 and rs9920 Donor Genotype on Long-Term Pancreas Transplant 
Function  
Bold represents any association seen after univariate analysis (P<0.20) or multivariate analysis (P<0.05). Simultaneous Pancreas Kidney (SPK, 
Pancreas After kidney (PAK), Pancreas Transplant Alone (PTA), Second Pancreas Transplant (2ND), Hazard Ratio (HR), Human Leukocyte 
Antigen (HLA), Body Mass Index (BMI), Donor After Brainstem Death (DBD) & Donor After Circulatory Death (DCD) 
  Univariate Analysis Multivariate Analysis of Cav1 
rs3801995 donor genotype 
Multivariate Analysis of Cav1 
rs9920 donor genotype 
  HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cav1 rs3801995 Overall Effect - - 0.015 - - 0.034    
 CC genotype 1 Reference  1 Reference     
 CT genotype 1.10 (0.69-1.75) 0.702 0.75 (0.54-1.05) 0.094    
 TT genotype 2.74 (1.38-5.44) 0.004 1.83 (1.16-2.89) 0.009    
           
Cav1 rs9902 TT genotype 1 Reference     1 Reference  
 CC/CT genotype 1.83 (1.14-2.93) 0.013    1.68 (1.03-2.73) 0.037 
           
           
Operation SPK 1 Reference  1 Reference  1 Reference  
 2ND 4.78 (2.26-10.15) 1.08x10-4 5.05 (2.37-10.76) 2.71x10-5 2.25 (1.28-3.97) 0.005 
 PAK 2.01 (1.04-3.88) 0.037 1.95 (0.95-4.02) 0.07 0.97 (0.58-1.62) 0.90 
 PTA 2.03 (1.19-3.47) 0.009 1.80 (1.06-3.42) 0.032 0.97 (0.63-1.48) 0.88 
Donor Type  DCD 1.00 Reference        
 DBD 0.80 (0.61-1.04) 0.097 0.90 (0.67-1.03) 0.48 0.89 (0.67-1.20) 0.45 
Donor  Age 1.01 (1.00-1.03) 0.149 1.02 (1.00-1.03) 0.07 1.02 (1.00-1.03) 0.94 
Donor BMI 1.01 (0.96-1.05) 0.845       
Donor Gender 1.21 (0.90-1.38) 0.315       
CIT  1.00 (1.00-1.00) 0.264       
Recipient Age 0.99 (0.96-1.01) 0.310       
Recipient BMI 1.01 (0.96-1.07) 0.694       
Recipient  Male (reference) 0.86 (0.68-1.07) 0.177 0.86 (0.68-1.09) 0.21 0.89 (0.70-1.12) 0.31 
HLA mismatch 5or6 (reference) 0.94 (0.74-1.19) 0.60       
                     
A: Log Rank X2=1.415, P=0.493
B: Log Rank X2=11.28, P=0.004
C: Log Rank X2=6.658, P=0.010
Supplementary Figure S1: Kaplan-Meier Plots for role of Cav1 rs4730751, rs3801995
and rs9920 SNP variation in Oxford Transplant Centre Donors and Recipients on
Long-Term Pancreas Graft function without those who received a second transplant
A: Kaplan-Meier plot for variation of Cav1 rs4730751 in Pancreas Transplant
Donors, B: Kaplan-Meier plot for variation of Cav1 rs3801995 in Pancreas
Transplant Donors, C: Kaplan-Meier plot for variation of Cav1 rs9920 in Pancreas
Transplant Donors
Supplementary Table S1: Cav1 tag SNPs screened in our Oxford Transplant Cohort and other common SNPs that they capture 
  
Tag SNP 
Screened  
Nucleotide 
variants 
present* 
Location of 
SNP on 
chromosome 
7 
SNP 
Type 
Variants Captured by tag SNP 
rs959173 T-C 115969290 Intronic rs959173, rs976739, rs1543293, rs6466586, rs6466584, rs6466583, rs3779514, rs1476833, rs6466585, rs2742125, 
rs1474510 & rs4727834 
rs3801995 C-T 115977833 Intronic rs3807990, rs729949, rs3757732, rs3757733, rs7804372, rs3801995, rs3807994, rs3807992, rs6466588 & rs3815412 
rs12672038 G-A 115974342 Intronic rs3807988, rs3807987, rs2052105, rs12672038, rs13233553, rs3807995, rs3801993, rs3801994, rs1049334 & 
rs12668226 
rs9886215 A-G 115978887 Intronic rs8713, rs9886219, rs2109516 ,rs9886215, rs6867, rs1049314 & rs6466587 
rs11773845 C-A 115978537 Intronic rs1997572, rs3807989 & rs11773845 
rs4730751 C-A 115968086 Intronic rs4730751, rs10270569 & rs10256914 
rs926198 T-C 115954444 Intronic rs926198 & rs917664 
rs3779512 G-T 115958299 Intronic rs9649394 & rs3779512 
rs9920 T-C 115987328 3’ UTR rs9920 
rs1049337 C-T 115987823 3’ UTR rs1049337 
rs3807986 A-G 115965061 Intronic rs3807986 
rs4730748 A-G 115954831 Intronic rs4730748 
All Tag SNP locations are based on NCBI Build 36 Assembly, dbSNP126, *=Major-minor allele nucleotides present at each tag SNP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S2: Cav1 Tag SNP genotype frequencies and Hardy Weinberg 
Equilibrium in our Oxford Pancreas Transplant donors and recipients 
 
Hardy Weinberg Equilibrium (HWE), Single Nucleotide Polymorphism (SNP) 
 
 
 
 
       Donors    Recipients  
Cav1 SNP Genotype N  (%) HWE 
X2 
HWE 
P 
N  (%) HWE  
X2 
HWE 
P 
          
rs959173 TT 295 (68.76) 3.12 0.08 304 (71.87) 1.56 0.21 
 TC 115 (26.81)   113 (26.71)   
 CC 19 (4.43)   6 (1.42)   
rs3801995 CC 253 (58.70) 0.01 0.93 226 (53.30) 0.28 0.60 
 CT 154 (35.73)   170 (40.09)   
 TT 24 (5.57)   28 (6.61)   
rs12672038 GG 370 (85.65) 0.85 0.36 369 (87.03) 0.60 0.44 
 AG 61 (14.12)   52 (12.26)   
 AA 1 (0.23)   3 (0.71)   
rs9886215 AA 296 (69.16) 1.48 0.22 267 (63.12) 2.05 0.15 
 AG 124 (28.67)   144 (34.04)   
 GG 8 (1.87)   12 (2.84)   
rs11773845 CC 149 (34.90) 0 0.96 141 (33.65) 0.33 0.57 
 CA 206 (48.24)   209 (49.88)   
 AA 72 (16.86)   69 (16.47)   
rs4730751 CC 219 (52.64) 3.67 0.06 192 (45.93) 2.65 0.10 
 CA 176 (42.31)   193 (46.17)   
 AA 21 (5.05)   33 (7.90)   
rs926198 TT 177 (40.88) 0.01 0.93 180 (42.55) 1.82 0.18 
 CT 199 (45.96)   182 (43.03)   
 CC 57 (13.16)   61 (14.42)   
rs3779512 GG 134 (31.31) 0.20 0.66 117 (27.92) 1.14 0.28 
 GT 215 (50.23)   219 (52.27)   
 TT 79 (18.46)   83 (19.81)   
rs9920 TT 353 (81.34) 2.60 0.11 325 (76.83) 5.09 0.02 
 CT 80 (18.43)   97 (22.93)   
 CC 1 (0.23)   1 (0.24)   
rs1049337 CC 239 (55.71) 0.01 0.91 219 (52.02) 0 0.96 
 CT 163 (38.00)   169 (40.14)   
 TT 27 (6.29)   33 (7.84)   
rs3807986 AA 243 (56.38) 0.15 0.70 253 (59.81) 4.76 0.03 
 AG 164 (38.05)   158 (37.35)   
 GG 24 (5.57)   12 (2.84)   
rs4730748 AA 282 (65.28) 2.36 0.12 260 (61.46) 0 0.95 
 AG 140 (32.41)   143 (33.81)   
 GG 10 (2.31)   20 (4.73)   
                   
Supplementary Table S3: Univariate and Multivariate Analysis of Cav1 rs3801995 and rs9920 Donor Genotype on Long-Term Pancreas 
Transplant Function with all those with a Second Transplant Removed 
Bold represents any association seen after univariate analysis (P<0.20) or multivariate analysis (P<0.05). Simultaneous Pancreas Kidney (SPK), 
Pancreas After kidney (PAK), Pancreas Transplant Alone (PTA), Hazard Ratio (HR), Human Leukocyte Antigen (HLA), Body Mass Index (BMI), 
Donor After Brainstem Death (DBD) & Donor After Circulatory Death (DCD) 
    Univariate Analysis Multivariate Analysis of Cav1 
rs3801995 donor genotype 
Multivariate Analysis of Cav1 
rs9920 donor genotype 
  HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cav1 rs3801995 Overall Effect - - 0.007 - - 0.034    
 CC genotype 1 Reference  1 Reference     
 CT genotype 1.17 (0.71-1.91) 0.544 1.05 (0.64-1.73) 0.86    
 TT genotype 3.06 (1.52-1.91) 0.002 2.52 (1.23-5.17) 0.011    
           
Cav1 rs9902 TT genotype 1 Reference     1 Reference  
 CC/CT genotype 1.85 (1.28-3.04) 0.015    1.67 (1.02-2.80) 0.043 
           
           
Operation SPK 1 Reference  1 Reference  1 Reference  
 PAK 2.00 (1.04-3.87) 0.039 1.24 (0.78-1.97) 0.37 1.97 (0.97-3.99) 0.60 
 PTA 2.04 (1.19-3.48) 0.009 1.23 (0.83-1.82) 0.30 2.02 (1.14-3.58) 0.017 
Donor Type  DCD  1.00 Reference        
 DBD 0.75 (0.57-0.98) 0.038 0.86 (0.64-1.17) 0.33 0.74 (0.41-1.34) 0.33 
Donor  Age 1.01 (1.00-1.03) 0.188 1.02 (1.00-1.04) 0.081 1.02 (1.00-1.03) 0.095 
Donor BMI 1.01 (0.96-1.05) 0.830       
Donor Gender 1.16 (0.92-1.45) 0.210       
CIT  1.00 (1.00-1.00) 0.255       
Recipient Age 0.99 (0.96-1.01) 0.281       
Recipient BMI 1.02 (0.96-1.09) 0.520       
Recipient  Male (reference) 0.85 (0.67-1.08) 0.177 0.86 (0.67-1.09) 0.21 0.76 (0.46-1.24) 0.27 
HLA mismatch 5or6 (reference) 0.90 (0.71-1.08) 0.403       
                     
